Cancer Research Technology
Log in Register
Menu

Anti-CD86, Recombinant [BU63]

Info

Catalogue Number 153266
Applications FACS IHC IF IP WB
Antigen/Gene or Protein Targets CD86
Synonyms B7.2
Reactivity Human
Relevance Recombinant monoclonal antibody directed against CD86 glycoprotein, without impacting on CTLA-4 activity. It aids the investigation of the adaptive immune response system.

Background and Research Application
CD86 is a 70 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors. CD86 was established during the 5th International Leukocyte Differentiation Antigen Workshop. CD86 is expressed on resting monocytes and dendritic cells, activated T and Natural Killer cells.
CD86 rapidly induced on the surface of activated B-cells and is the ligand for two different proteins on the T cell surface: CD28, for autoregulation and intercellular association, and CTLA-4, for attenuation of regulation and cellular disassociation. CD86 works in tandem with CD80 to prime T cells in the primary immune response. CD86 is also expressed by malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.
This is a recombinant version of anti-CD86 monoclonal antibody. Anti-CD86 BU63, alongside another monoclonal antibody, helped define CD86 single-chain cell-surface protein expressed by blood monocytes and activated B cells. This antibody does not block CTLA-4 binding to B7-2/B70, but induces a conformational change in CD86 which increases the binding affinity of soluble CTLA-4.
Host Mouse
Immunogen ARH 77 (B-lymphoblastoid cell line)
Subclass IgG1
Formulation PBS
Concentration 1mgml-1
Research Area Immunology
Immunogen UniProt ID P42081
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Anti-CD86 helped show that CD86 and B7-2B70 are the same molecule.
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Five different variants available:
- Anti-CD86 [BU63], Mouse IgG1, Kappa
- Anti-CD86 [BU63], Rabbit IgG, Kappa
- Anti-CD86 [BU63], Human IgG1, Kappa
- Anti-CD86 [BU63], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-CD86 [BU63], Human IgG4-S228P, Kappa

Concentration
1mg/ml as standard

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Original hybridoma first published in: Nozawa et al. 1993. J Pathol. 169(3):309-15. PMID: 8492223.

Santos et al. 2019. Immunology. 157(4):296-303. PMID: 31162836.


Add a reference

References: 2 entries

Original hybridoma first published in: Nozawa et al. 1993. J Pathol. 169(3):309-15. PMID: 8492223.

Santos et al. 2019. Immunology. 157(4):296-303. PMID: 31162836.


Add a reference

Inventor Information